Brussels, 22 Sep 2005
Introducing you to healthcare biotechnology
An overview of EU policies in biotechnology: the Lisbon agenda and beyond
European biotech industry leaders publish a new Healthcare Manifesto. More than 250 million patients to date have benefited from biotech medicines to treat or prevent heart attacks, Multiple Sclerosis, breast cancer, cystic fibrosis, leukaemia and other diseases including rare disorders. But many patients do not have access to treatments and many diseases are still untreated.
The manifesto, published by EuropaBio sets out seven key policies to meet the healthcare innovations expected over the next few years to meet unmet medical needs.
- The role of economic evaluation of biotechnology medicines and emerging technologies
- Biosimilar Medicinal Products: raising the bar of quality and safety - a public health
perspective
- Orphan Drugs: completing a European dream
- Reaching for new medical frontiers with emerging cell & tissue engineered products
- Bioethics as an invaluable component in today's healthcare industry
- Diagnosis and innovative medicines go hand in hand: towards targeted therapies, the role of genetics and pharmacogenetics
Biotech to biotech: where size matters: creating a friendly environment for SME's and the biotech industry
EUROPABIO
Item source: http://www.healthcare-manifesto.org/
Previous Item
Back to Titles
Print Item